ESTRO 36 Abstract Book

228 / 1082

S215 ESTRO 36 2017
_______________________________________________________________________________________________
dosimetrically of these anatomical changes as well. In
addition, DIBH mitigates lung tumour motion. However,
DIBH has not yet gained wide implementation in this
patient group.
In this talk, some of the most widely applied techniques
for DIBH will be presented, together with addressing the
DIBH compliance of lung cancer patients. Intra- and
interfractional reproducibility of tumour position and the
differential motion of the lymph nodes relative to the
peripheral tumour has to be evaluated for DIBH
radiotherapy as well, since these uncertainties have
impact on planning target volume (PTV) margins in photon
radiotherapy and robustness of the proton therapy.
In radiotherapy of patients with locally advanced lung
cancer, the relatively high doses delivered to the healthy
tissue, result in treatment related toxicity. DIBH offers a
potential to reduce irradiation of the heart structures, the
lungs and the oesophagus, potentially improving toxicity
risks.
When treating in DIBH, image guidance has to be
performed in DIBH as well. The optimal modalities will be
discussed, with their impact on treatment uncertainties.
Radiotherapy for early stage lung cancer is delivered with
stereotactic body radiotherapy (SBRT, or SABR). In this
patient group motion mitigation is a bigger challenge than
toxicity risks. Very small mobile tumours may not be
visualised on cone beam C T (CBCT), used for radiotherapy
image guidance and hence SBRT cannot be delivered
safely. With improved image quality in DIBH, small
tumours can be visualised on daily CBCTs and safe and fast
treatment can be delivered within 3-4 DIBHs of 20 seconds
duration with flattening filter free beam.
Symposium: Education and research grants
SP-0410 ERC grants - how to succeed
M. Vooijs 1
1 MAASTRO GROW School for Oncology, Radiation
Oncology, Maastricht, The Netherlands
The mission of the European Research Council (ERC) is to
encourage the highest quality research in Europe through
competitive funding and to support investigator-driven
frontier research across all fields, on the basis of scientific
excellence. ERC grants fund basic science and technology
of intrinsically risky projects, progressing in new and the
most exiting research areas and characterised by the
absence of disciplinary boundaries. In this interactive
lecture I will discuss my experiences with obtaining ERC
grants. If you are attending and interested in writing an
ERC grant I encourage you to send me your questions /
experiences by email in advance:
SP-0411 ESTRO educational grants and mobility grants
M.C. Vozenin1
1 Centre Hospitalier Universitaire Vaudois, Department of
Radiation Oncology, Lausanne Vaud, Switzerland
ESTRO educational grants and mobility grants will be
presented in detail along with specific advices and
presentation of the required format that will enable you
to submit a successful application.
SP-0412 ESTRO educational grant - if you don't try,
you won't win
M. Spalek1
1 The Maria Sklodowska-Curie Memorial Cancer Center,
Radiotherapy, Warsaw, Poland
Young and confused. A first year radiation oncology
resident - a totally new field of knowledge, new people,
demanding tasks and high expectations. I was trying to
find a good source of knowledge, contacts and possibilities
for an ambitious physician. Then I discovered ESTRO and
the section of ESTRO School courses. The offer looked
excellent, but the fee and costs of travel with
accommodation were unbearable without financial
support. 'GRANTS & FELLOWSHIP' tab was promising. And
finally - educational grant for young radiation oncology
professionals. I thought that I will try - why not? I did not
expect that I will be chosen (a newbie without a strong
scientific background) and... I was wrong. I awarded the
grant. Evidence-based Radiation Oncology in Varna,
Bulgaria - that was my choice.
During my presentation I will tell a story of my application,
try to find possible reasons of the success, tell some
practical information about realization, present useful
tips and sum up the whole adventure with ESTRO
educational grant.
SP-0413 ESTRO mobility grant - establishing intravital
brain imaging in preclinical models
J. Birch1, L. Gilmore1, A. Chalmers1
1Institute of Cancer Sciences, Translational Radiation
Biology, Glasgow, United Kingdom
Glioblastoma (GBM) is an aggressive form of primary adult
brain tumour that typically has a very poor clinical
outcome and a very high rate of disease recurrence. The
high recurrence rates are thought to be due in part to the
invasive nature of glioblastoma cells, which allows them
to infiltrate the healthy brain tissue surrounding the
tumour mass and thereby preventing complete surgical
resection and limiting the radiation dose that can be safely
delivered to the target volume.
Our lab is studying the mechanisms by which glioblastoma
(GBM) cells are able to invade normal brain tissue and
testing the efficacy of putative anti-invasive agents on
these processes. However, modelling GBM invasion using
in vitro approaches is both challenging and limited: it is
impossible to recapitulate the complex 3-dimensional
structure of the brain in an in vitro setting. In order to
address this issue we wanted to use an in vivo approach,
combined with intravital imaging of the brain, to
complement and strengthen in vitro observations. This
approach involves the establishment of patient-derived
xenograft tumours in the brains of immuno-compromised
mice via intracranial injection of fluorescently labelled
primary human glioblastoma cell lines. An intracranial
window is then created which allows real time imaging of
glioblastoma tumour cells in situ using multiphoton
microscopy.
In order to establish this complex technique in our lab, we
arranged to visit an expert in this field, Dr. Frank Winkler,
whose lab routinely use brain intravital imaging of GBM.
The primary objective of the visit was for the acquisition
and optimization of the necessary skills to establish high
quality intravital imaging of the brain at our own institute.
We were also interested in establishing valuable
communication links with a laboratory that is active and
expert in this field that might have the potential to lead
to collaborations in the future.
During our visit we observed in detail the surgical
techniques that are required to inject glioblastoma
tumour cells into the brain and create the intracranial
windows necessary to allow intravital imaging. The setting
up of this technique is a challenging and involved
procedure and this opportunity to witness it first hand was
extremely valuable. We were able to gauge the timescale
required for establishment in our own lab as well as
equipment and reagents that we will have to source to
make it possible. Our hosts in Heidelberg also generously
arranged to send an experienced lab member to Glasgow
to help improve our surgical technique.
From this initial visit we established a second
collaboration with the lab of Prof. Jim Norman at the
Beatson Institute of Cancer Research which was